Latest Stallergenes Stories
RnRMarketResearch.com adds "Allergy Diagnostics Market by Allergen Source (Food Allergens, Inhaled Allergens), Product (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) & by End User (Hospital,
DALLAS, December 8, 2014 /PRNewswire/ -- According to the new market research report "Allergy Diagnostics Market by Allergen Source (Food Allergens, Inhaled Allergens),
STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX's technology for targeted delivery of allergen-based treatments ANTONY, France and GHENT,
MarketOptimizer.org adds “OpportunityAnalyzer Allergic Rhinitis – Allergen-Specific Immunotherapy – Opportunity Analysis and Forecast to 2018” to its store.
In a move that could replace allergy shots for some men and women, the US Food and Drug Administration announced on Wednesday that it had approved the first tablet for the treatment of hay fever symptoms.
ANTONY, France, November 10, 2010 /PRNewswire-FirstCall/ -- Following the announcement that Wendel had entered exclusive negotiations with Ares Life Sciences on October 28, 2010, with a view to selling its entire stake (around 46%) in Stallergenes, the company's Works Council met on November 10, 2010. Stallergenes' Works Council having returned a positive consultative opinion at this meeting, Wendel and Ares Life Sciences proceeded to sign a firm transfer agreement. It is in this...
PARIS, November 27 /PRNewswire-FirstCall/ -- Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure.
PARIS, August 26 /PRNewswire-FirstCall/ -- - Net Profit Up 11% - Strong Research and Investment Effort - Positive net Financial Position - Annual Growth Guidance Maintained at 10% The Board of Directors, meeting on 25 August 2009 under the chairmanship of Albert Saporta approved the 2009 half year financial statements: In million Euros H1 2008 08/07 H1 2009 %CA Var.% %CA Sales...
- To give a box on the ear to.